Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed Adults
A Randomized Non-Inferiority Trial to Compare the Efficacy of Switching From Protease-Inhibitor Based Second-Line Therapy to Bictegravir-Tenofovir Alafenamide-Emtricitabine in Virologically Suppressed Adults in Haiti
Sponsor: Analysis Group, Inc.
This PHASE4 trial investigates Antiretroviral Therapy and HIV-1-infection and is currently ongoing. Analysis Group, Inc. leads this study, which shows 7 recorded versions since 2020 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE4
Status: Unknown Status → Unknown
-
Feb 2023 — Jul 2024 [monthly]
Unknown Status PHASE4
Status: Not Yet Recruiting → Unknown Status
-
Jan 2022 — Feb 2023 [monthly]
Not Yet Recruiting PHASE4
-
Jan 2021 — Jan 2022 [monthly]
Not Yet Recruiting PHASE4
▶ Show 2 earlier versions
-
Sep 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE4
-
Apr 2020 — Sep 2020 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Analysis Group, Inc.
- Brigham and Women's Hospital
- Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic
- Harvard Medical School (HMS and HSDM)
- Weill Medical College of Cornell University
For direct contact, visit the study record on ClinicalTrials.gov .